丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

000513 丽珠集团

已收盘 11-19 15:00:00

{"stockData":{"symbol":"000513","market":"SZ","secType":"STK","nameCN":"丽珠集团","latestPrice":37.74,"timestamp":1731999837000,"preClose":37.12,"halted":0,"volume":7757917,"delay":0,"floatShares":601000000,"shares":927000000,"eps":2.1833,"marketStatus":"已收盘","marketStatusCode":5,"change":0.62,"latestTime":"11-19 15:00:00","open":37.3,"high":37.95,"low":37.25,"amount":292000000,"amplitude":0.0189,"askPrice":37.74,"askSize":88,"bidPrice":37.73,"bidSize":34,"shortable":0,"etf":0,"ttmEps":2.1833,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732066200000},"adr":0,"adjPreClose":37.12,"symbolType":"stock","openAndCloseTimeList":[[1731979800000,1731987000000],[1731992400000,1731999600000]],"highLimit":40.83,"lowLimit":33.41,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":927459624,"pbRate":2.43,"roa":"--","roe":"11.63%","epsLYR":2.1,"committee":-0.663717,"marketValue":35002000000,"floatMarketCap":22665000000,"peRate":17.28576,"changeRate":0.0167,"turnoverRate":0.0129,"status":0},"requestUrl":"/m/hq/s/000513","defaultTab":"news","newsList":[{"id":"2484645167","title":"丽珠集团11月18日现1笔大宗交易 成交金额8671.15万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484645167","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484645167?lang=zh_cn&edition=full","pubTime":"2024-11-18 17:00","pubTimestamp":1731920400,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 　　11月18日，丽珠集团平收，收盘价为37.12元，发生1笔大宗交易，合计成交量233.6万股，成交金额8671.15万元。　　第1笔成交价格为37.12元，成交233.60万股，成交金额8,671.15万元，溢价率为0.00%，买方营业部为机构专用，卖方营业部为机构专用。　　进一步统计，近3个月内该股累计发生1笔大宗交易，合计成交金额为8671.15万元。该股近5个交易日累计下跌2.50%，主力资金合计净流出7183.83万元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-11-18/doc-incwnsqi3475375.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-11-18/doc-incwnsqi3475375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0187","BK0188","BK0239","000513"],"gpt_icon":0},{"id":"2483858412","title":"丽珠集团获得发明专利授权：“新的二肽类化合物及其用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2483858412","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483858412?lang=zh_cn&edition=full","pubTime":"2024-11-16 03:36","pubTimestamp":1731699381,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示丽珠集团新获得一项发明专利授权，专利名为“新的二肽类化合物及其用途”，专利申请号为CN201980082261.3，授权日为2024年11月15日。今年以来丽珠集团新获得专利授权5个，较去年同期减少了44.44%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111600007921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000513","BK0028","BK0239","BK0187","BK0188"],"gpt_icon":0},{"id":"2480071124","title":"丽珠集团(000513.SZ)已耗资约3.3亿元回购930万股A股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2480071124","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480071124?lang=zh_cn&edition=full","pubTime":"2024-11-01 17:03","pubTimestamp":1730451803,"startTime":"0","endTime":"0","summary":"智通财金APP讯，丽珠集团(000513.SZ)发布公告，截至2024年10月31日，公司通过集中竞价交易方式回购了公司A股股份共计930万股，占公司总股本的比例为1.00%，购买的最高价为人民币37.45元/股，最低价为人民币32.95元/股，已使用的资金总额为人民币3.3亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1205634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","000513","159982","BK0239","399300","BK0188","BK0028"],"gpt_icon":0},{"id":"2480340044","title":"太平洋：给予丽珠集团买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2480340044","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480340044?lang=zh_cn&edition=full","pubTime":"2024-11-01 12:11","pubTimestamp":1730434280,"startTime":"0","endTime":"0","summary":"太平洋证券股份有限公司谭紫媚,张懿近期对丽珠集团进行研究并发布了研究报告《丽珠集团：制剂放量略慢，潜在大单品有望获批》，本报告对丽珠集团给出买入评级，当前股价为37.39元。2024年前三季度实现营业收入47.14亿元，同比下降8.52%。诊断试剂及设备产品实现营业收入5.66亿元，同比增长21.03%。最新盈利预测明细如下：该股最近90天内共有11家机构给出评级，买入评级10家，增持评级1家；过去90天内机构目标均价为44.38。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100020198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601099","000513"],"gpt_icon":0},{"id":"2479071187","title":"丽珠集团：10月31日接受机构调研，东吴证券、富国基金参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2479071187","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479071187?lang=zh_cn&edition=full","pubTime":"2024-10-31 19:23","pubTimestamp":1730373801,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年10月31日丽珠集团发布公告称公司于2024年10月31日接受机构调研，东吴证券分析师 张坤 研究员 张翀翯、富国基金基金经理 王超 研究员 杨波参与。前三季度中药制剂产品实现收入 10.41 亿元，同比下降 16.49%。该公司的产品销往中国境内和海外市场。丽珠集团2024年三季报显示，公司主营收入90.82","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100039256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0009","BK0188","BK0183","BK0028","601555","BK0012","BK0239","BK0187","000513","BK0276"],"gpt_icon":0},{"id":"2478159313","title":"丽珠集团：10月25日接受机构调研，东吴证券、东方红资管参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2478159313","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478159313?lang=zh_cn&edition=full","pubTime":"2024-10-27 18:22","pubTimestamp":1730024539,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年10月25日丽珠集团发布公告称公司于2024年10月25日接受机构调研，东吴证券分析师 张坤 研究员 刘若彤、东方红资管基金经理助理 刘中群 研究员 徐宏参与。答：目前丽珠集团对丽珠单抗持股占比 56.87%。集团将继续梳理单抗公司业务，将做好费用控制。相关购股份均用于注销并减少公司注册资本。丽珠集团主营业务：主要从事医药产品的研发、生产和销售业务的中国公司。该公司的产品销往中国境内和海外市场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102700013824.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000513","BK0028","601555","BK0276","BK0239","BK0187","BK0183","BK0012","BK0188","BK0009"],"gpt_icon":0},{"id":"2478023153","title":"华福证券：给予丽珠集团买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2478023153","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478023153?lang=zh_cn&edition=full","pubTime":"2024-10-27 17:40","pubTimestamp":1730022025,"startTime":"0","endTime":"0","summary":"华福证券有限责任公司陈铁林近期对丽珠集团进行研究并发布了研究报告《业绩短期承压，在研管线稳步推进，看好公司长期发展》，本报告对丽珠集团给出买入评级，当前股价为37.51元。原料药和中间体收入25.2亿元，同比下降2.6%。诊断试剂及设备收入5.7亿元，同比增长21%。前三季度公司利息收入为1.5亿，同比减少1.3亿元。最新盈利预测明细如下：该股最近90天内共有11家机构给出评级，买入评级10家，增持评级1家；过去90天内机构目标均价为44.38。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102700013587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","000513"],"gpt_icon":0},{"id":"2478507608","title":"东海证券：给予丽珠集团买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2478507608","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478507608?lang=zh_cn&edition=full","pubTime":"2024-10-25 16:52","pubTimestamp":1729846372,"startTime":"0","endTime":"0","summary":"东海证券股份有限公司杜永宏,伍可心近期对丽珠集团进行研究并发布了研究报告《公司简评报告：业绩符合预期，研发顺利推进》，本报告对丽珠集团给出买入评级，当前股价为37.51元。注射用阿立哌唑微球2023年报产，目前已提交发补材料，预计2025年上半年获批。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有11家机构给出评级，买入评级10家，增持评级1家；过去90天内机构目标均价为44.38。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500027803.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","000513"],"gpt_icon":0},{"id":"2477370192","title":"丽珠集团最新公告：前三季度净利润16.73亿元 同比增长4.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477370192","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477370192?lang=zh_cn&edition=full","pubTime":"2024-10-23 16:51","pubTimestamp":1729673480,"startTime":"0","endTime":"0","summary":"丽珠医药集团股份有限公司发布2024年第三季度报告，前三季度实现营业收入90.82亿元，同比下降5.94%；归属于上市公司股东的净利润16.73亿元，同比增长4.44%；基本每股收益1.81元。第三季度实现营业收入27.99亿元，同比下降5.59%；归属于上市公司股东的净利润5.02亿元，同比增长7.45%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102300027319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000513"],"gpt_icon":0},{"id":"2477377085","title":"丽珠集团(000513.SZ)发布前三季度业绩，净利润16.73亿元，同比增长4.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477377085","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477377085?lang=zh_cn&edition=full","pubTime":"2024-10-23 16:49","pubTimestamp":1729673396,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠集团(000513.SZ)发布2024年三季度报告，前三季度，公司实现营业收入90.82亿元，同比下降5.94%。归属于上市公司股东的净利润16.73亿元，同比增长4.44%。归属于上市公司股东的扣除非经常性损益的净利润16.31亿元，同比增长3.51%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1198030.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000513"],"gpt_icon":0},{"id":"2475579972","title":"丽珠集团(000513.SZ)：注射用醋酸亮丙瑞林微球通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2475579972","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475579972?lang=zh_cn&edition=full","pubTime":"2024-10-15 19:03","pubTimestamp":1728990238,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠集团 发布公告，近日，公司控股子公司上海丽珠制药有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，上海丽珠制药有限公司生产的注射用醋酸亮丙瑞林微球通过注射剂仿制药质量和疗效一致性评价。注射用醋酸亮丙瑞林微球每4周皮下注射一次，具有起效时间长、用药次数少等特点，可减轻患者痛苦和用药负担，提高用药耐受性和可及性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1194337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000513","BK0239","BK0028","BK0188","BK0187"],"gpt_icon":0},{"id":"2475705520","title":"丽珠集团最新公告：注射用醋酸亮丙瑞林微球通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2475705520","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475705520?lang=zh_cn&edition=full","pubTime":"2024-10-15 18:19","pubTimestamp":1728987569,"startTime":"0","endTime":"0","summary":"丽珠集团公告，控股子公司上海丽珠制药有限公司生产的注射用醋酸亮丙瑞林微球通过注射剂仿制药质量和疗效一致性评价。该药品为《国家基本医疗保险、工伤保险和生育保险药品目录》乙类品种，适应症包括子宫内膜异位症、绝经前乳腺癌、前列腺癌等。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101500029703.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000513","BK0028","BK0239","BK0187","BK0188"],"gpt_icon":0},{"id":"2475355047","title":"丽珠集团：关于公司董事辞职的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2475355047","media":"新浪财经-鹰眼工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475355047?lang=zh_cn&edition=full","pubTime":"2024-10-14 17:41","pubTimestamp":1728898860,"startTime":"0","endTime":"0","summary":"丽珠医药集团股份有限公司关于公司董事辞职的公告本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。丽珠医药集团股份有限公司董事会于2024年10月14日收到俞雄先生向公司董事会递交的书面辞呈。因工作调整原因，俞雄先生自愿辞去公司董事一职，辞职后不在公司及控股子公司任职。丽珠医药集团股份有限公司董事会2024年10月15日","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-10-14/doc-incspmqw8140623.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-10-14/doc-incspmqw8140623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK0028","BK0239","BK0187","000513"],"gpt_icon":0},{"id":"2473423426","title":"丽珠集团(000513.SZ)：注射用醋酸曲普瑞林微球新适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2473423426","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473423426?lang=zh_cn&edition=full","pubTime":"2024-10-08 19:33","pubTimestamp":1728387206,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠集团 发布公告，近日，公司及控股子公司上海丽珠制药有限公司收到国家药品监督管理局核准签发的《药品注册证书》，公司注射用醋酸曲普瑞林微球新适应症“子宫内膜异位症”获得注册批准。本品是每月一次肌肉注射的一种促性腺激素释放激素激动剂，相比普通醋酸曲普瑞林注射剂，具有起效时间长，减少用药次数特点，可减轻患者痛苦和用药负担，提高用药耐受性和可及性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1191210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0028","BK0239","BK0187","000513"],"gpt_icon":0},{"id":"2473434984","title":"丽珠集团(000513.SZ)已累计回购0.85%股份 耗资约2.77亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2473434984","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473434984?lang=zh_cn&edition=full","pubTime":"2024-10-08 17:13","pubTimestamp":1728378826,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠集团(000513.SZ)发布公告，截至2024年9月30日，公司通过集中竞价交易方式回购了公司A股股份共计785.5万股，占公司总股本的比例为0.85%，购买的最高价为人民币36.80元/股，最低价为人民币32.95元/股，已使用的资金总额为人民币2.77亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1191028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK0028","000513","BK0239","BK0188"],"gpt_icon":0},{"id":"2471076841","title":"《大行》花旗列出中国最少“拥挤交易”主题买入股票名单(表)","url":"https://stock-news.laohu8.com/highlight/detail?id=2471076841","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471076841?lang=zh_cn&edition=full","pubTime":"2024-09-30 12:50","pubTimestamp":1727671800,"startTime":"0","endTime":"0","summary":"花旗发表报告表示，鉴于内地最近政策转变导致中国投资者情绪出现强于预期的逆转，一直对中国持负面看法的投资者现在正竞相减少以往减持头寸。到目前为止，该行已看到最大的反弹来自非“拥挤交易”的产业和股票。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180509171357285_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180509171357285_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1384955&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["000513","002230","83189","603345","01929","03189","601727","600276","IQ","603799","00291","000002","002812","CRHKY","002074","02319","600809","603259","00968","00881","002050","06837","600570","300059","000858","603806","02607","002281","000568","00390","01093","EVS.SI","00168","600048","00916","80291","00688","600085","01066","00392","02238","002236","159982","06881","002460","000963","399300"],"gpt_icon":1},{"id":"2470850422","title":"【机构调研记录】泓德基金调研丽珠集团、燕京啤酒","url":"https://stock-news.laohu8.com/highlight/detail?id=2470850422","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470850422?lang=zh_cn&edition=full","pubTime":"2024-09-25 08:01","pubTimestamp":1727222506,"startTime":"0","endTime":"0","summary":"泓德基金成立于年，截至目前，资产管理规模477.15亿元，排名88/207；资产管理规模446.88亿元，排名75/207；管理公募基金数70只，排名80/207；旗下公募基金经理18人，排名72/207。旗下最近一年表现最佳的公募基金产品为泓德裕泰债券A，最新单位净值为1.42，近一年增长4.94%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092500005891.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0012","000513","000729","BK0215","BK0239","BK0187"],"gpt_icon":0},{"id":"2470240094","title":"【机构调研记录】汇安基金调研丽珠集团","url":"https://stock-news.laohu8.com/highlight/detail?id=2470240094","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470240094?lang=zh_cn&edition=full","pubTime":"2024-09-25 08:01","pubTimestamp":1727222503,"startTime":"0","endTime":"0","summary":"旗下最近一年表现最佳的公募基金产品为汇安裕鑫12个月定开纯债债券，最新单位净值为1.06，近一年增长13.54%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092500005881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000513","BK0239","BK0028","BK0187"],"gpt_icon":0},{"id":"2470422862","title":"【机构调研记录】国联基金调研丽珠集团","url":"https://stock-news.laohu8.com/highlight/detail?id=2470422862","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470422862?lang=zh_cn&edition=full","pubTime":"2024-09-25 08:01","pubTimestamp":1727222488,"startTime":"0","endTime":"0","summary":"旗下最近一年表现最佳的公募基金产品为国联恒泽纯债C，最新单位净值为1.12，近一年增长8.6%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092500005859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0187","BK0188","000513"],"gpt_icon":0},{"id":"2470223324","title":"【机构调研记录】华安基金调研丽珠集团、弘信电子","url":"https://stock-news.laohu8.com/highlight/detail?id=2470223324","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470223324?lang=zh_cn&edition=full","pubTime":"2024-09-25 08:01","pubTimestamp":1727222480,"startTime":"0","endTime":"0","summary":"压感方案中公司目前为独供，该项目由于市场需求尚未完全起量，故出货量不大。；公司产品已经成功应用到多个客户的多教智能眼镜及AR、VR硬件产品中华安基金成立于1998年，截至目前，资产管理规模6413.83亿元，排名16/207；资产管理规模3784.57亿元，排名14/207；管理公募基金数479只，排名11/207；旗下公募基金经理69人，排名12/207。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092500005850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000513","BK0028","BK0187","BK0188","BK0239","BK0214","BK0201","300657"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1993-10-28","address":"广东省珠海市金湾区创业北路38号总部大楼","stockEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":-0.0303},{"period":"3month","weight":0.0139},{"period":"6month","weight":0.0076},{"period":"1year","weight":0.1244},{"period":"ytd","weight":0.0997}],"companyName":"丽珠医药集团股份有限公司","boardCode":"AI0027","perCapita":"14541股","boardName":"医药制造业","registeredCapital":"92745万元","compareEarnings":[{"period":"1week","weight":-0.0421},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.1595},{"period":"6month","weight":0.0523},{"period":"1year","weight":0.0882},{"period":"ytd","weight":0.1173}],"survey":"　　丽珠医药集团股份有限公司以医药产品的研发、生产及销售为主业，主要产品涵盖制剂产品、原料药和中间体及诊断试剂及设备，主要产品包括壹丽安（艾普拉唑肠溶片及注射用艾普拉唑钠）、丽珠得乐（枸橼酸铋钾）系列产品、丽倍乐（雷贝拉唑钠肠溶胶囊）、维三联（枸橼酸铋钾片/替硝唑片/克拉霉素片）、贝依（注射用醋酸亮丙瑞林微球）、丽申宝（注射用尿促卵泡素）、乐宝得（注射用尿促性素）、丽福康（注射用伏立康唑）、瑞必乐（马来酸氟伏沙明片）、康尔汀（盐酸哌罗匹隆片）、参芪扶正注射液、抗病毒颗粒等制剂产品；美伐他汀、阿卡波糖、硫酸粘菌素、苯丙氨酸、盐酸万古霉素、达托霉素、米尔贝肟及头孢曲松钠等原料药和中间体；肺炎支原体IgM抗体检测试剂（胶体金法）、人类免疫缺陷病毒抗体诊断试剂盒（酶联免疫法）及抗核抗体检测试剂盒（磁条码免疫荧光发光法）等诊断试剂产品。","serverTime":1732012199075,"listedPrice":6.38,"stockholders":"41299人(较上一季度减少1.41%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供丽珠集团(000513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"丽珠集团,000513,丽珠集团股票,丽珠集团股票老虎,丽珠集团股票老虎国际,丽珠集团行情,丽珠集团股票行情,丽珠集团股价,丽珠集团股市,丽珠集团股票价格,丽珠集团股票交易,丽珠集团股票购买,丽珠集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供丽珠集团(000513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}